Latest Financial Results
Q3 2023
Quarter Ended Dec 31, 2022
Latest 10-K
View Latest 10-KStock Information
Symbol
Nasdaq: AEMDPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
Aethlon Medical develops immunotherapeutic technologies to combat infectious disease and cancer. To augment the body's natural immune defenses, the Aethlon Hemopurifier® reduces the presence of circulating viruses in infected individuals. The technology provides a first-line candidate defense against viruses that are not addressed with proven drug therapies, including natural occurring pandemic threats and agents of bioterrorism. The Hemopurifier® can also be deployed as a strategy to improve the benefit of approved antiviral drug regimens. At present, the Hemopurifier® is being advanced in the United States under an FDA approved clinical study. Aethlon Medical is also investigating the potential use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.
IR Contact Information
Aethlon Medical, Inc.
11555 Sorrento Valley Road
Suite 203
San Diego, CA 92121
Investor Relations
S. A. Noonan Communications
Susan Noonan
Managing Partner
susan@sanoonan.com
Transfer Agent
Computershare Investor Services
P.O. Box 30170
College Station, TX 77842-3170
T: 781-575-2000
www.computershare.com